The Child with Immune Thrombocytopenic Purpura

Is Pharmacotherapy or Watchful Waiting the Best Initial Management? A Panel Discussion from the 2002 Meeting of the American Society of Pediatric Hematology/Oncology

Paula Bolton-Maggs, Michael D. Tarantino, George R. Buchanan, James B. Bussel, James N. George

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The initial management of immune thrombocytopenic purpura is a topic of debate among pediatric hematologists. The decision whether to start a patient on pharmacotherapy or to employ an approach of watchful waiting and patient education is problematic for this group of physicians. A wide variety of research studies and review articles have been published on either side of this debate. Here, the proceedings from a panel discussion, held at the 2002 American Society of Pediatric Hematology/Oncology meeting, are presented. The panel, composed of experts on both sides of the debate, presented the rationale, benefits, and risks of both pharmacotherapy and the watchful waiting strategy.

Original languageEnglish (US)
Pages (from-to)146-151
Number of pages6
JournalJournal of Pediatric Hematology/Oncology
Volume26
Issue number2
DOIs
StatePublished - Feb 2004

Fingerprint

Watchful Waiting
Idiopathic Thrombocytopenic Purpura
Hematology
Pediatrics
Drug Therapy
Patient Education
Physicians
Research

Keywords

  • Anti-D
  • Idiopathic (immune) thrombocytopenic purpura
  • Immune globulin
  • Intracranial hemorrhage
  • Platelets

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

@article{d7bc9236d6a849e28b82e696ff3783fa,
title = "The Child with Immune Thrombocytopenic Purpura: Is Pharmacotherapy or Watchful Waiting the Best Initial Management? A Panel Discussion from the 2002 Meeting of the American Society of Pediatric Hematology/Oncology",
abstract = "The initial management of immune thrombocytopenic purpura is a topic of debate among pediatric hematologists. The decision whether to start a patient on pharmacotherapy or to employ an approach of watchful waiting and patient education is problematic for this group of physicians. A wide variety of research studies and review articles have been published on either side of this debate. Here, the proceedings from a panel discussion, held at the 2002 American Society of Pediatric Hematology/Oncology meeting, are presented. The panel, composed of experts on both sides of the debate, presented the rationale, benefits, and risks of both pharmacotherapy and the watchful waiting strategy.",
keywords = "Anti-D, Idiopathic (immune) thrombocytopenic purpura, Immune globulin, Intracranial hemorrhage, Platelets",
author = "Paula Bolton-Maggs and Tarantino, {Michael D.} and Buchanan, {George R.} and Bussel, {James B.} and George, {James N.}",
year = "2004",
month = "2",
doi = "10.1097/00043426-200402000-00020",
language = "English (US)",
volume = "26",
pages = "146--151",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - The Child with Immune Thrombocytopenic Purpura

T2 - Is Pharmacotherapy or Watchful Waiting the Best Initial Management? A Panel Discussion from the 2002 Meeting of the American Society of Pediatric Hematology/Oncology

AU - Bolton-Maggs, Paula

AU - Tarantino, Michael D.

AU - Buchanan, George R.

AU - Bussel, James B.

AU - George, James N.

PY - 2004/2

Y1 - 2004/2

N2 - The initial management of immune thrombocytopenic purpura is a topic of debate among pediatric hematologists. The decision whether to start a patient on pharmacotherapy or to employ an approach of watchful waiting and patient education is problematic for this group of physicians. A wide variety of research studies and review articles have been published on either side of this debate. Here, the proceedings from a panel discussion, held at the 2002 American Society of Pediatric Hematology/Oncology meeting, are presented. The panel, composed of experts on both sides of the debate, presented the rationale, benefits, and risks of both pharmacotherapy and the watchful waiting strategy.

AB - The initial management of immune thrombocytopenic purpura is a topic of debate among pediatric hematologists. The decision whether to start a patient on pharmacotherapy or to employ an approach of watchful waiting and patient education is problematic for this group of physicians. A wide variety of research studies and review articles have been published on either side of this debate. Here, the proceedings from a panel discussion, held at the 2002 American Society of Pediatric Hematology/Oncology meeting, are presented. The panel, composed of experts on both sides of the debate, presented the rationale, benefits, and risks of both pharmacotherapy and the watchful waiting strategy.

KW - Anti-D

KW - Idiopathic (immune) thrombocytopenic purpura

KW - Immune globulin

KW - Intracranial hemorrhage

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=0442324869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0442324869&partnerID=8YFLogxK

U2 - 10.1097/00043426-200402000-00020

DO - 10.1097/00043426-200402000-00020

M3 - Article

VL - 26

SP - 146

EP - 151

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 2

ER -